KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
COMPASS: deCOMPressing stomA and two-Stage elective resection vs. emergency reSection in patients with left-sided obstructive colon cancer. PMID 37798612 · Trials · 2023-Oct-05 Protocol abstract for an ongoing randomized trial comparing surgical strategies in colon cancer; no results, no drug intervention, primary endpoint is short-term mortality, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preconditioning of the motor network with repetitive navigated transcranial magnetic stimulation (rnTMS) to improve oncological and functional outcome in brain tumor surgery: a study protocol for a randomized, sham-controlled, triple-blind clinical trial. PMID 37794435 · Trials · 2023-Oct-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. PMID 37665777 · Oncologist · 2023-Oct-03 The report is from a Phase III randomized trial but focuses exclusively on cardiac safety (LVEF and cardiac AEs). It does not present or include a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. PMID 37487056 · Oncologist · 2023-Oct-03 The record does not meet the eligibility criteria because it is not a report from a randomized controlled trial (specifically, a Phase III/IIIb or Phase II/III randomized trial). The study is a retrospective, non-randomized real-world analysis. While it includes a drug intervention and time-to-event endpoints, the lack of randomization and definitive trial phase (Phase III/IIIb or Phase II/III) makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. PMID 37339254 · Oncologist · 2023-Oct-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial. PMID 37315114 · Oncologist · 2023-Oct-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Overall Survival After Treatment Failure Among Patients With Rectal Cancer. PMID 37902752 · JAMA Netw Open · 2023-Oct-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival. PMID 37878313 · JAMA Netw Open · 2023-Oct-02 The record describes a retrospective cohort analysis of data from four randomized adjuvant chemotherapy trials. While it reports time-to-event outcomes (OS, RFS) and involves drug interventions, the report itself is not the primary result publication for any of the individual trials. It is a secondary analysis focused on racial/ethnic disparities, making its report_type 'secondary'. The phase of the referenced trials is not definitively established in the abstract metadata as Phase III/IIIb for all, preventing confirmation of that criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial. PMID 37847504 · JAMA Netw Open · 2023-Oct-02 Eligibility is excluded because the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided record. All other required criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) are met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 37801315 · JAMA Netw Open · 2023-Oct-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dual tracer navigation for lymph node dissection in laparoscopic radical gastrectomy (DANCE trial): a protocol for a prospective, randomized clinical trial. PMID 37784191 · Trials · 2023-Oct-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Correction: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. PMID 37783482 · Int J Gynecol Cancer · 2023-Oct-02 Title indicates Phase III randomized trial with drug intervention in oncology (ovarian cancer). However, abstract is empty, so cannot establish human subjects, time-to-event endpoint (OS/PFS/etc.), or that this is a primary result report (vs. correction/erratum).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Side effects screening and early intervention to impact in quality of life of patients with gynecological cancers (HALIS study). PMID 37748803 · Int J Gynecol Cancer · 2023-Oct-02 This is a clinical trial protocol for a randomized study on quality of life in gynecological cancer patients. It is not an original result report, lacks a drug intervention, and does not have a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial. PMID 37494539 · Clin Cancer Res · 2023-Oct-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial. PMID 37439809 · Clin Cancer Res · 2023-Oct-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma. PMID 38185869 · Indian J Cancer · 2023-Oct-01 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original results. However, it is excluded because the primary efficacy endpoint is complete response rate (CR), and the secondary endpoint is overall response rate (ORR). Neither is a time-to-event endpoint. No Kaplan-Meier survival curves or hazard ratios for time-to-event outcomes (OS, PFS, etc.) are reported in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 37561451 · JAMA Oncol · 2023-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Prospective Randomized Clinical Study of Minimally Invasive Video-assisted Thyroidectomy for Papillary Thyroid Microcarcinoma. PMID 37556410 · Surg Laparosc Endosc Percutan Tech · 2023-Oct-01 The study is a randomized surgical trial for thyroid cancer, but it lacks a drug-containing intervention and does not report a formal time-to-event efficacy endpoint (like OS or PFS) with Kaplan-Meier or hazard ratio analysis. The primary endpoints are surgical and immediate postoperative outcomes, and recurrence was absent (0 events) in both groups, which does not constitute a reportable time-to-event result for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. PMID 37535388 · JAMA Oncol · 2023-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. PMID 37535377 · JAMA Oncol · 2023-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Patients With Cancer Who Smoke. PMID 37467454 · J Clin Oncol · 2023-Oct-01 The study is a randomized oncology trial with original results, but it is ineligible because it does not involve a drug-containing intervention and its primary endpoint is not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer. PMID 37466971 · JAMA Surg · 2023-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings. PMID 37368929 · J Acquir Immune Defic Syndr · 2023-Oct-01 The study is a randomized trial in oncology (Kaposi sarcoma) with a drug intervention (etoposide), but it is a secondary biomarker analysis, not a primary efficacy report. The primary endpoint is not time-to-event (response prediction by biomarkers at week 48 is described, but not as a formal KM or HR analysis). Phase is not established. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant intensity modulated radiotherapy for a single and small (≤5 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial. PMID 37352528 · Int J Surg · 2023-Oct-01 The study is a randomized controlled trial in oncology with human subjects and a time-to-event primary endpoint (DFS). However, it is not eligible because: 1) The trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata or abstract (it is labeled as a 'Randomized Clinical Trial' without a specified phase). 2) The experimental intervention is neoadjuvant radiotherapy (a non-drug therapy) followed by surgery, which does not meet the drug-intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial. PMID 37335984 · Int J Surg · 2023-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). PMID 37294914 · J Clin Oncol · 2023-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Single-Masked Randomized Phase 2 Study Assessing 2 Forms of Hypofractionated Proton Therapy in Patients With Large Choroidal Melanomas. PMID 37257661 · Int J Radiat Oncol Biol Phys · 2023-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Blood Perfusion Assessment by Indocyanine Green Fluorescence Imaging for Minimally Invasive Rectal Cancer Surgery (EssentiAL trial): A Randomized Clinical Trial. PMID 37218517 · Ann Surg · 2023-Oct-01 The study is an original Phase 3 randomized trial in oncology (rectal cancer), but it evaluates a diagnostic/imaging intervention (ICG-FI) to reduce surgical complication rates, not a therapeutic drug. The primary endpoint is anastomotic leakage rate, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the drug intervention or time-to-event endpoint criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early Detection of Brain Metastases in a Supervised Exercise Program for Patients with Advanced Breast Cancer: A Case Report. PMID 37170950 · Med Sci Sports Exerc · 2023-Oct-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. PMID 37102598 · Haematologica · 2023-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. PMID 36951156 · Haematologica · 2023-Oct-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. PMID 36661037 · Ann Surg · 2023-Oct-01 This is an original report from a randomized, Phase II/III trial (RAPIDO trial) in human oncology with a drug-containing intervention and a time-to-event endpoint (locoregional failure). However, the report is a 5-year follow-up analysis of a secondary endpoint (locoregional failure) and not a primary or key secondary efficacy endpoint (like OS or PFS). The trial phase is not explicitly stated as Phase III in the provided metadata, and the analysis focuses on a secondary endpoint (locoregional failure patterns), making it a secondary analysis report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial. PMID 41647283 · ESMO Gastrointest Oncol · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Meta-analysis and trial sequential analysis of Chaihuang Granules in treatment of upper respiratory tract infection in children]. PMID 38114127 · Zhongguo Zhong Yao Za Zhi · 2023-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus. PMID 37869406 · Open Forum Infect Dis · 2023-Oct The report is a secondary analysis from a randomized trial, focusing on biomarker associations with clinical outcomes, not the primary efficacy report of the drug intervention with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Narrow Band Imaging versus White Light for the Detection of Sessile Serrated Colorectal Lesions: A Randomized Clinical Trial. PMID 37868631 · GE Port J Gastroenterol · 2023-Oct The study is an eligible randomized trial in oncology but fails two key criteria: it lacks a drug intervention (it is a diagnostic imaging comparison) and it does not report a time-to-event efficacy endpoint (the endpoints are detection counts/rates, not survival or progression).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking. PMID 37856212 · J Natl Compr Canc Netw · 2023-Oct The study is a randomized controlled trial in oncology, but its primary endpoint is health-related quality of life (HRQoL), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP). The eligibility criteria require a primary/key secondary time-to-event efficacy endpoint with a Kaplan-Meier or HR, which is not the focus of this report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. PMID 37840530 · Cancer Med · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III. PMID 37824431 · Cancer Med · 2023-Oct The study is a Phase III, single-arm trial in oncology (breast cancer) evaluating a drug intervention (pegfilgrastim biosimilar). However, it does not meet the required criterion of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc., with Kaplan-Meier or HR analysis). The endpoints are hematologic (duration of neutropenia, incidence of febrile neutropenia). Additionally, the trial is not randomized.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. PMID 37814061 · Nat Med · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma. PMID 37805963 · Hematol Oncol · 2023-Oct The abstract describes commentary on three large, phase III, randomized trials and preliminary results from an ongoing phase 2 study (RAFTING). No specific time-to-event efficacy endpoints (e.g., OS, PFS) or corresponding Kaplan-Meier/HR results are reported. The publication is a commentary/article summarizing trials, not an original formal result report of a single trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Survival outcomes and surgical morbidity based on surgical approach to pulmonary metastasectomy in pediatric, adolescent and young adult patients with osteosarcoma. PMID 37800658 · Cancer Med · 2023-Oct The study is an oncology human retrospective study with original results, but it is not randomized, does not report a Phase III or definitive trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint like OS/PFS/KM/HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial. PMID 37787025 · Cancer Med · 2023-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of a one-year personalized intensive dietary intervention on body composition in colorectal cancer patients: Results from a randomized controlled trial. PMID 37739688 · Clin Nutr ESPEN · 2023-Oct The study is a randomized controlled trial in oncology (colorectal cancer) and reports primary results, but it does not meet all inclusion criteria. The intervention is dietary (non-drug), and the primary outcomes are changes in body composition (weight, fat mass), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design and methods of a randomized telehealth-based intervention to improve fitness in survivors of childhood cancer with exercise intolerance. PMID 37730199 · Contemp Clin Trials · 2023-Oct The record is a clinical trial protocol for a non-drug intervention (exercise/telehealth) in childhood cancer survivors. It does not report results for a time-to-event efficacy endpoint (OS, PFS, etc.) or use Kaplan-Meier/HR analysis. The study is randomized and oncology-related, but it is a Phase II/III trial protocol without completed results, and the intervention is not drug-containing.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. PMID 37704166 · Ann Oncol · 2023-Oct The record describes an oncology RCT with a time-to-event primary endpoint (OS) and a drug-containing intervention. However, the text does not explicitly state that this is a Phase III, IIIb, or combined Phase II/III trial. The deterministic review signal correctly identifies the lack of explicit Phase III/IIIb evidence. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects. PMID 37701913 · J Bone Oncol · 2023-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial. PMID 37683518 · J Diabetes Complications · 2023-Oct 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[CT-Based Weighted Radiomic Score Predicts Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer]. PMID 37674467 · Zhongguo Yi Xue Ke Xue Yuan Xue Bao · 2023-Oct The study is an original randomized trial in oncology patients with a drug intervention, but its primary endpoint is categorical tumor response (assessed by AUC), not a time-to-event outcome. Therefore, it does not meet the core criterion for a time-to-event efficacy endpoint. Additionally, the trial phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results. PMID 37670198 · Cardiovasc Intervent Radiol · 2023-Oct The study is a randomized controlled trial with a drug-eluting stent intervention and reports time-to-event endpoints (primary patency, freedom from TLR, survival). However, the condition treated (femoropopliteal peripheral arterial disease) is not a human malignant neoplasm, which is the foundational requirement for inclusion in this oncology-focused cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -